Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Palatin Technologies's PL-9643?
PL-9643 is a synthetic peptide commercialized by Palatin Technologies, with a leading Phase III program in Keratoconjunctivitis Sicca (Dry Eye)....
PL-9643 by Palatin Technologies for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval
PL-9643 is under clinical development by Palatin Technologies and currently in Phase III for Keratoconjunctivitis Sicca (Dry Eye). According to...
Risk adjusted net present value: What is the current valuation of Palatin Technologies's PL-9643?
PL-9643 is a synthetic peptide commercialized by Palatin Technologies, with a leading Phase III program in Keratoconjunctivitis Sicca (Dry Eye)....